Firm's Talicia pill combats H. pylori bacteria, a major carcinogen which affects some 2 million US adults

Israeli firm plans to start selling the pill in the US in first quarter 2020, targeting more than 2 million patients treated for H. pylori infection annually; shares surge

If the Talicia drug to combat H. pylori bacterial infection gets approved, commercial launch is planned for the fourth quarter of 2019, Israeli firm says